A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint Inhibitor Naïve Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Avelumab (Primary) ; Hu5F9 G4 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Forty Seven
- 07 Jan 2019 According to a Forty Seven media release, the company expects to report the data from the trial in the fourth quarter of 2019.
- 13 Aug 2018 According to Forty Seven media release, Dosed First Patient has been dosed.
- 03 Jun 2018 Status changed from planning to recruiting, according to a Forty Seven media release,.